All News

House Bill (HB) 1993 seeks to increase PBM transparency and accountability in an effort to combat the rising cost of prescription drugs.

Patients using isCGM had reduced glucose variability, time in low glucose range, time in very low glucose range, and less events related to low glucose levels.

In part 2 of the latest episode of Over the Counter, Mayank Amin, PharmD, RPh, MBA, discusses his journey as the Superman Pharmacist and expresses hope for the future of community pharmacy.

Mayank Amin, PharmD, RPh, MBA, sat down with Drug Topics on part 1 of an episode of Over the Counter to share his experiences transforming a shuttered independent pharmacy into a thriving community hub.

Emporos announced a strategic partnership with InterLink AI to help pharmacists streamline tasks and fill more prescriptions.

“If people think COVID is no big deal and decide to forgo vaccinations, they’re essentially doubling their risk of developing long COVID,” wrote investigators.

The retail pharmacy chain issued an alert to its customers that purchasing data from 2017 to 2018 may have been breached by a third party.

Patients with childhood type 1 diabetes were more likely to develop substance use disorders, mood disorders, anxiety disorders, and behavioral syndromes.

The CDC issued a report on the state of the avian influenza, or bird flu, at the end of last week.

As the end of the DSCSA stabilization period approaches, Scott Mooney, vice president of distribution operations at McKesson, discussed what pharmacists should consider to be prepared.

COVID-19 patients had reduced absolute granulocyte, monocyte, and lymphocyte counts at 10 months post-infection compared to noninfected individuals.

Look back at some of the amazing insights during McKesson ideaShare, the premier event for community pharmacists.

Researchers compared health care and prescription medication affordability during the COVID-19 pandemic to pre-pandemic numbers.

Farron Dozier, former sergeant first class in the US Army, sat down with Drug Topics on a recent episode of Over the Counter to discuss his experience with PTSD.

In case you missed it, this week we had news about FTC-backed PBM investigations, FDA approvals in atopic dermatitis, misconceptions about dry eye, and more.

Check out this recap of articles published on our sister sites during the past week.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Researchers aimed to address the extent of stigmatization’s effect on the mental health of adolescents with chronic skin disorders.

Pfizer joins Eli Lilly and Novo Nordisk in the development of oral GLP-1 receptor agonist candidates.

Global coverage for diphtheria, tetanus, and pertussis has reached its lowest point in 15 years.

“They may not understand. But I tell people, ‘I don't want you to understand me.’ I don't understand me. But if you can relate to me, then that furthers our conversation—the relatedness,” said Farron Dozier on his experience with PTSD.

Calcitonin gene-related peptides are known to trigger vasodilation and inflammation.

Had Novo Nordisk’s insulin icodec secured FDA approval, it would have been the first and only once-weekly basal insulin option for adults with diabetes.

A former sergeant first class in the US Army discussed PTSD in an exclusive interview with Drug Topics.

The commercial product is expected to be available by the end of July.

The study’s mixed findings on telehealth for opioid use disorder (OUD) treatment suggest a need for more individualized approaches to care.

Chris Cella, RPh, vice president of RxOwnership at McKesson, talks about how independent pharmacies can help improve their bottom line.

McKesson’s private brand of OTC health and wellness products are a great way for independent pharmacies to increase profits.

The FTC released its interim report detailing PBM practices, staggering market consolidation statistics, and the disparities between PBMs and their smaller competitors.

When used together, sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were able to lower the risk of major adverse cardiovascular events and kidney disease by 11% and 33%, respectively.